CN113337570A - Mechanism analysis system for drug target of depression and drug addiction disease - Google Patents
Mechanism analysis system for drug target of depression and drug addiction disease Download PDFInfo
- Publication number
- CN113337570A CN113337570A CN202110589629.4A CN202110589629A CN113337570A CN 113337570 A CN113337570 A CN 113337570A CN 202110589629 A CN202110589629 A CN 202110589629A CN 113337570 A CN113337570 A CN 113337570A
- Authority
- CN
- China
- Prior art keywords
- drug
- experimental
- output
- input
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010013663 drug dependence Diseases 0.000 title claims abstract description 27
- 208000011117 substance-related disease Diseases 0.000 title claims abstract description 27
- 239000003596 drug target Substances 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 21
- 238000004458 analytical method Methods 0.000 title claims abstract description 20
- 230000007246 mechanism Effects 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 119
- 229940079593 drug Drugs 0.000 claims abstract description 102
- 238000012216 screening Methods 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000002331 protein detection Methods 0.000 claims abstract description 12
- 230000001575 pathological effect Effects 0.000 claims abstract description 6
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 67
- 239000003112 inhibitor Substances 0.000 claims description 32
- 108010078791 Carrier Proteins Proteins 0.000 claims description 30
- 102000014914 Carrier Proteins Human genes 0.000 claims description 29
- 230000009471 action Effects 0.000 claims description 29
- 239000012268 protein inhibitor Substances 0.000 claims description 29
- 229940121649 protein inhibitor Drugs 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- 229940126585 therapeutic drug Drugs 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 210000004958 brain cell Anatomy 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 20
- 241000699670 Mus sp. Species 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 15
- 210000004556 brain Anatomy 0.000 claims description 14
- 239000002504 physiological saline solution Substances 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000003147 molecular marker Substances 0.000 claims description 9
- 238000007877 drug screening Methods 0.000 claims description 8
- 210000005013 brain tissue Anatomy 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 238000012606 in vitro cell culture Methods 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 238000000464 low-speed centrifugation Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 230000003001 depressive effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 description 14
- 238000010586 diagram Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- GEDJUAKXFJRZSG-UHFFFAOYSA-N 7-[3-[(3-acetylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound CC(=O)c1cccc(OCc2nn(C)c(C)c2-c2cccc3c(CCCOc4cccc5ccccc45)c([nH]c23)C(O)=O)c1 GEDJUAKXFJRZSG-UHFFFAOYSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- -1 immune systems Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a mechanism analysis system of a drug target for depression and drug addiction diseases, which comprises the following steps of selecting a proper object, an experimental object, drug treatment, protein detection and immune tissue screening: the method comprises the following steps: selecting a mouse group with more active vital signs from a young healthy mouse group as an experimental group; step two: the invention relates to a method for treating the disease of a selected rat group, which comprises the steps of carrying out pathological treatment on the selected rat group, and putting addictive drugs into the feed of the rat group.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical mechanism analysis, and particularly relates to a mechanism analysis system of a drug target for depression and drug addiction diseases.
Background
Depression is the most common depressive disorder, with significant and persistent mood swings as the primary clinical feature, the major type of mood disorder. The low mood is not matched with the situation in clinic, the depression of the mood can be from sultriness to sadness, and the self-declining depression and even the pessimism are taken away, and suicide attempts or behaviors can be caused; even the occurrence of stupor; in some cases, there is significant anxiety and motor agitation; in severe cases, psychotic symptoms such as hallucinations and delusions may occur. Each episode lasts at least 2 weeks, more than long, or even years, and most cases have a tendency to have recurrent episodes, most of which can be alleviated, and some of which can have residual symptoms or become chronic.
The combining position of the medicine and the organism biomacromolecule is the medicine target. The drug action targets relate to receptors, enzymes, ion channels, transporters, immune systems, genes and the like. In addition, some drugs act by their physicochemical actions or by supplementing substances that the body lacks. In the existing medicines, more than 50 percent of medicines take receptors as action targets, and the receptors become the most main and important action targets; more than 20% of the drugs take enzyme as an action target, particularly enzyme inhibitors, and have special positions in clinical application; about 6% of the drugs take ion channels as action targets; 3% of the medicine takes nucleic acid as an action target; the action targets of 20% of the drugs are still to be further researched.
In the existing treatment process of depression and drug addiction diseases, a drug target mechanism is not studied in detail, and scientific research personnel cannot know the specific action position of a drug molecule and the type of a drug carrier, so that the drug molecule cannot act on a specified position in the treatment process, and the treatment effect of the drug molecule is influenced.
Disclosure of Invention
The technical problem to be solved by the invention is to overcome the existing defects and provide a mechanism analysis system of a drug target for depression and drug addiction diseases, so as to solve the problem that the mechanism of the drug target is not deeply researched in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a mechanism analysis system of drug targets for depression and drug addiction diseases, comprising selection of suitable subjects, drug treatment, protein detection and immune tissue screening, comprising the steps of:
the method comprises the following steps: selecting a mouse group with more active vital signs from a young healthy mouse group as an experimental group;
step two: carrying out pathological treatment on the selected mouse group, putting addictive drugs into the mouse group feed to enable the mouse group to generate dependence on the drugs, feeding the mouse group in a closed and narrow dark environment, and culturing for several days, and then taking the mouse group as an experimental object;
step three: classifying experimental mouse group objects, injecting different carrier protein inhibitors into the experimental mouse group objects in different types of experimental mouse groups, injecting therapeutic drugs into the experimental mouse groups after the inhibitors are injected, and screening effective carrier protein inhibitors by observing the activity conditions of the experimental mouse groups;
step four: adding marked fluorescein into the drug molecules of another group of experimental mice, observing the drug molecules through a microscope, selecting the successfully marked drug molecules, injecting the marked drug molecules into the experimental mice, acting for a period of time, and taking out the brain cells of the mice;
step five: after the brain cells are taken out, different tissues in the brain cells are separated by adopting a low-speed centrifugation technical means, the different tissues are observed through a microscope, the specific action area of the drug molecules is obtained, and the experimental result is analyzed and recorded.
Preferably, the output end of the selected suitable subject is respectively connected with the input ends of the depression treatment and the drug addiction treatment, the output ends of the depression treatment and the drug addiction treatment are respectively connected with the input end of the screening subject, and the output end of the screening subject is connected with the input end of the acquired experimental subject.
Preferably, the output of subject and the input of injection treatment medicine interconnect, the output of injection treatment medicine and the input that adds different carrier protein inhibitors interconnect, the output that adds different carrier protein inhibitors and the input that observes subject's sign condition interconnect, the output that observes subject's sign condition and the input that screens carrier protein inhibitors interconnect.
Preferably, the output of subject and the input interconnect of injection treatment medicine, the output of injection treatment medicine and the input interconnect of drawing materials in brain district, the output of drawing materials in brain district and the input interconnect of obtaining brain district protein, the output of obtaining brain district protein and the input interconnect of protein detection.
Preferably, the output end of the drug treatment is connected with the input end of the drug molecular marker, the output end of the drug molecular marker is connected with the input end of the marker drug screening, and the output end of the marker drug screening is connected with the input end of the marker drug storage.
Preferably, the input end of the protein detection and the input end of the immune tissue screening are connected with each other, the output end of the immune tissue screening and the input end of the marking region observation are connected with each other, and the output end of the marking region observation and the input end for acquiring the action position of the drug are connected with each other.
Preferably, the output end of the experimental object is respectively connected with the input ends of the protein carrier inhibitor and the physiological saline, and the output ends of the protein carrier inhibitor and the physiological saline are respectively connected with the input end of the screening object.
Preferably, the output end of the immune tissue screening and the input end of the low-speed centrifugal screening are connected with each other, the output end of the low-speed centrifugal screening and the input end of the different cell tissues are connected with each other, and the output end of the different cell tissues and the input ends of the classified storage are connected with each other.
Preferably, the output end of the experimental object is connected with the input end for obtaining brain tissue cells, and the output end for obtaining brain tissue cells is connected with the input end for in vitro cell culture.
Preferably, the output end of the in vitro cell culture is respectively connected with the input ends of a protein carrier inhibitor and physiological saline, the output ends of the protein carrier inhibitor and the physiological saline are respectively connected with the input end of an injection therapeutic drug, and the output end of the injection therapeutic drug is connected with the input end of the observation cell shape.
Compared with the prior art, the invention provides a mechanism analysis system of a drug target for depression and drug addiction diseases, which has the following beneficial effects:
1. the invention adopts the drug molecule marking to the therapeutic drug, and selects the successfully marked drug molecules from the marked drug, injects the drug molecules into the mouse body, and carries out low-speed centrifugal screening on the mouse brain cells after the drug molecules act for a period of time, and observes the different drug target point acting tissue positions of the brain cells through a microscope, so that the drug molecule acting target point positions can be intuitively observed, thereby facilitating scientific research personnel to act the drug on the appointed position;
2. according to the invention, different carrier protein inhibitors are added into the experimental mouse group, and therapeutic drugs are injected into the experimental mouse group added with different carrier protein inhibitors, so that the mice group is a drug carrier inhibitor in a more tedious way compared with the mice group by observing the physical sign condition after the drug action of the experimental mouse group, and is a carrier required by the drug in the opposite situation, and the specific type of the therapeutic drug carrier can be obtained by the way, so that scientific research personnel can know the drug carrier required by the therapeutic drug;
3. the invention can compare the action effect of the treatment drug under the action of the drug carrier inhibitor with the treatment effect of the treatment drug without adding the drug carrier inhibitor by observing the morphological characteristics of the brain cells in vitro under a microscope so as to facilitate scientific researchers to directly observe the treatment effect condition of the treatment drug without a carrier.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention without limiting the invention in which:
FIG. 1 is a system framework diagram of a subject obtained from the mechanism analysis system of drug targets for depression and drug addiction diseases proposed by the present invention;
FIG. 2 is a system block diagram of carrier protein inhibitor screening in the mechanistic analysis system proposed by the present invention for drug targets in depression and drug addiction diseases;
FIG. 3 is a system block diagram of protein detection in the mechanistic analysis system proposed by the present invention for drug targets in depression and drug addiction diseases;
FIG. 4 is a system block diagram of the molecular markers of drugs in the mechanistic analysis system of drug targets for depression and drug addiction diseases proposed by the present invention;
FIG. 5 is a system block diagram of the region of action of drug molecules in a mechanistic analysis system for drug targets for depression and drug addiction diseases in accordance with the present invention;
FIG. 6 is a system block diagram of subject screening in a mechanistic analysis system for drug targets for depression and drug addiction diseases in accordance with the present invention;
FIG. 7 is a system framework diagram of different tissue cells obtained from the mechanistic analysis system of drug targets for depression and drug addiction diseases proposed by the present invention;
FIG. 8 is a system block diagram of in vitro cell culture in a mechanistic analysis system for drug targets for depression and drug addiction diseases in accordance with the present invention.
In the figure: 1. selecting a suitable object; 2. treating depression; 3. drug addiction treatment; 4. screening objects; 5. obtaining an experimental object; 6. (ii) an experimental subject; 7. injecting a therapeutic agent; 8. adding different carrier protein inhibitors; 9. observing the physical sign condition of the experimental subject; 10. screening a carrier protein inhibitor; 11. taking materials from a brain area; 12. obtaining brain region protein; 13. detecting protein; 14. treating with a medicament; 15. labeling drug molecules; 16. screening labeled drugs; 17. marking the drug storage; 18. screening immune tissues; 19. observing a marked area; 20. acquiring the action position of the medicine; 21. a protein carrier inhibitor; 22. physiological saline; 23. low-speed centrifugal screening; 24. obtaining different cell tissues; 25. storing in a classified manner; 26. obtaining brain tissue cells; 27. culturing cells in vitro; 28. the cell morphology was observed.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1-8, the present invention provides the following technical solutions: a mechanistic analysis system for drug targets for depression and drug addiction diseases comprising selecting suitable subjects 1, subjects 6, drug treatment 14, protein detection 13 and immune tissue screening 18, comprising the steps of:
the method comprises the following steps: selecting a mouse group with more active vital signs from a young healthy mouse group as an experimental group;
step two: carrying out pathological treatment on the selected mouse group, putting addictive drugs into the mouse group feed to enable the mouse group to generate dependence on the drugs, feeding the mouse group in a closed and narrow dark environment, and culturing for several days, and then taking the mouse group as an experimental object;
step three: classifying experimental mouse group objects, injecting different carrier protein inhibitors into the experimental mouse group objects in different types of experimental mouse groups, injecting therapeutic drugs into the experimental mouse groups after the inhibitors are injected, and screening effective carrier protein inhibitors by observing the activity conditions of the experimental mouse groups;
step four: adding marked fluorescein into the drug molecules of another group of experimental mice, observing the drug molecules through a microscope, selecting the successfully marked drug molecules, injecting the marked drug molecules into the experimental mice, acting for a period of time, and taking out the brain cells of the mice;
step five: after the brain cells are taken out, different tissues in the brain cells are separated by adopting a low-speed centrifugation technical means, the different tissues are observed through a microscope, the specific action area of the drug molecules is obtained, and the experimental result is analyzed and recorded.
In the present invention, it is preferable that the output terminal of the selected suitable subject 1 is connected to the input terminals of the depressive process 2 and the drug addiction process 3, respectively, the output terminals of the depressive process 2 and the drug addiction process 3 are connected to the input terminal of the selected subject 4, and the output terminal of the selected subject 4 is connected to the input terminal of the acquisition subject 5.
In the present invention, preferably, the output end of the experimental subject 6 is connected to the input end of the injection therapeutic drug 7, the output end of the injection therapeutic drug 7 is connected to the input end of the different carrier protein inhibitors 8, the output end of the different carrier protein inhibitors 8 is connected to the input end of the experimental subject for observing the physical sign condition 9, and the output end of the experimental subject for observing the physical sign condition 9 is connected to the input end of the screening carrier protein inhibitor 10.
In the present invention, preferably, the output end of the subject 6 and the input end of the injection treatment drug 7 are connected to each other, the output end of the injection treatment drug 7 and the input end of the brain region material 11 are connected to each other, the output end of the brain region material 11 and the input end of the brain region protein 12 are connected to each other, and the output end of the brain region protein 12 and the input end of the protein detection 13 are connected to each other.
In the present invention, preferably, the output terminal of the drug processing 14 and the input terminal of the drug molecular marker 15 are connected to each other, the output terminal of the drug molecular marker 15 and the input terminal of the marker drug screening 16 are connected to each other, and the output terminal of the marker drug screening 16 and the input terminal of the marker drug storage 17 are connected to each other.
In the present invention, it is preferable that the input terminal of the protein assay 13 and the input terminal of the immunohistoscreening 18 are connected to each other, the output terminal of the immunoscreening 18 and the input terminal of the labeling area observing 19 are connected to each other, and the output terminal of the labeling area observing 19 and the input terminal of the drug action site 20 are connected to each other.
In the present invention, preferably, the output terminal of the subject 6 is connected to the input terminals of the protein carrier inhibitor 21 and the physiological saline 22, respectively, and the output terminals of the protein carrier inhibitor 21 and the physiological saline 22 are connected to the input terminal of the screening target 4.
In the present invention, it is preferable that the output terminal of the immunohistological screening 18 and the input terminal of the low-speed centrifugal screening 23 are connected to each other, the output terminal of the low-speed centrifugal screening 23 and the input terminal of the differential cellular tissue 24 are connected to each other, and the output terminal of the differential cellular tissue 24 and the input terminal of the sorting container 25 are connected to each other.
In the present invention, it is preferable that the output terminal of the subject 6 and the input terminal for obtaining the brain tissue cells 26 are connected to each other, and the output terminal for obtaining the brain tissue cells 26 and the input terminal for the in vitro cell culture 27 are connected to each other.
In the present invention, preferably, the output end of the cell in vitro culture 27 is connected to the input ends of the protein carrier inhibitor 21 and the physiological saline 22, respectively, the output ends of the protein carrier inhibitor 21 and the physiological saline 22 are connected to the input end of the injection therapeutic drug 7, and the output end of the injection therapeutic drug 7 is connected to the input end of the observation cell morphology 28.
The first embodiment is as follows:
a mechanistic analysis system for drug targets for depression and drug addiction diseases comprising selecting suitable subjects 1, subjects 6, drug treatment 14, protein detection 13 and immune tissue screening 18, comprising the steps of:
the method comprises the following steps: selecting a mouse group with more active vital signs from a young healthy mouse group as an experimental group;
step two: carrying out pathological treatment on the selected mouse group, putting addictive drugs into the mouse group feed to enable the mouse group to generate dependence on the drugs, feeding the mouse group in a closed and narrow dark environment, and culturing for several days, and then taking the mouse group as an experimental object;
step three: classifying experimental mouse group objects, injecting different carrier protein inhibitors into the experimental mouse group objects in different types of experimental mouse groups, injecting therapeutic drugs into the experimental mouse groups after the inhibitors are injected, and screening effective carrier protein inhibitors by observing the activity conditions of the experimental mouse groups;
step four: adding marked fluorescein into the drug molecules of another group of experimental mice, observing the drug molecules through a microscope, selecting the successfully marked drug molecules, injecting the marked drug molecules into the experimental mice, acting for a period of time, and taking out the brain cells of the mice;
step five: after the brain cells are taken out, different tissues in the brain cells are separated by adopting a low-speed centrifugation technical means, the different tissues are observed through a microscope, the specific action area of the drug molecules is obtained, and the experimental result is analyzed and recorded.
Example two:
a mechanistic analysis system for drug targets for depression and drug addiction diseases comprising selecting suitable subjects 1, subjects 6, drug treatment 14, protein detection 13 and immune tissue screening 18, comprising the steps of:
the method comprises the following steps: selecting a mouse group with more active vital signs from a young healthy mouse group as an experimental group;
step two: carrying out pathological treatment on the selected mouse group, putting addictive drugs into the mouse group feed to enable the mouse group to generate dependence on the drugs, feeding the mouse group in a closed and narrow dark environment, and culturing for several days, and then taking the mouse group as an experimental object;
step three: classifying experimental mouse group objects, injecting different carrier protein inhibitors into the experimental mouse group objects in different types of experimental mouse groups, injecting therapeutic drugs into the experimental mouse groups after the inhibitors are injected, and screening effective carrier protein inhibitors by observing the activity conditions of the experimental mouse groups;
step four: adding marked fluorescein into the drug molecules of another group of experimental mice, observing the drug molecules through a microscope, selecting the successfully marked drug molecules, injecting the marked drug molecules into the experimental mice, acting for a period of time, and taking out the brain cells of the mice;
step five: after the brain cells are taken out, different tissues in the brain cells are separated by adopting a low-speed centrifugation technical means, the different tissues are observed through a microscope, the specific action area of the drug molecules is obtained, and the experimental result is analyzed and recorded.
In the invention, preferably, the output end of the experimental subject 6 is connected with the input end for injecting the therapeutic drug 7, the output end for injecting the therapeutic drug 7 is connected with the input end for adding different carrier protein inhibitors 8, the output end for adding different carrier protein inhibitors 8 is connected with the input end for observing the physical signs of the experimental subject 9, the output end for observing the physical signs of the experimental subject 9 is connected with the input end for screening the carrier protein inhibitor 10, the experimental rat group is added with different carrier protein inhibitors, the therapeutic drug is injected into the experimental rat group added with different carrier protein inhibitors, the rat group is a drug carrier inhibitor more clumsy than the rat group by observing the physical signs after the drug action of the experimental rat group, and is a carrier required by the drug under the opposite condition, and the specific type of the therapeutic drug carrier can be obtained by the mode, so that scientific research personnel can know the medicine carrier needed by the treatment medicine.
In the invention, preferably, the output end of the drug treatment 14 is connected with the input end of the drug molecular marker 15, the output end of the drug molecular marker 15 is connected with the input end of the marker drug screening 16, the output end of the marker drug screening 16 is connected with the input end of the marker drug storage 17, the drug molecular marker is adopted for the treatment drug, the successfully marked drug molecules are screened from the marked drug, the drug molecules are injected into a mouse body, the mouse brain cells after the drug molecules act for a period of time are subjected to low-speed centrifugal screening, and the action tissue positions of different drug target points of the brain cells are observed by a microscope, so that the action target point positions of the drug molecules can be visually observed, and scientific researchers can conveniently act the drug on the designated position.
In the present invention, preferably, the output end of the cell in vitro culture 27 is connected to the input ends of the protein carrier inhibitor 21 and the normal saline 22, respectively, the output ends of the protein carrier inhibitor 21 and the normal saline 22 are connected to the input end of the injection therapeutic drug 7, the output end of the injection therapeutic drug 7 is connected to the input end of the observation cell morphology 28, by performing in vitro cell culture experiment on rat brain cells, injecting protein carrier inhibitor and normal saline with the same concentration into two different cells, and then injecting therapeutic drugs into the two cells, by observing morphological characteristics of the in-vitro brain cells under a microscope, the action effect of the treatment drug under the action of the drug carrier inhibitor can be compared with the treatment effect of the treatment drug without adding the drug carrier inhibitor, so that scientific research personnel can directly observe the treatment effect condition of the treatment drug without the carrier.
By integrating the above embodiments, by injecting the protein carrier inhibitor and the physiological saline with the same concentration into two different cells, and then injecting the therapeutic drug into the two cells, and observing morphological characteristics of the brain cells in vitro under a microscope, under the comparison condition of the action effect of the therapeutic drug under the action of the drug carrier inhibitor and the therapeutic effect of the therapeutic drug without the drug carrier inhibitor, the in vitro cell activity degree containing the drug carrier inhibitor is lower, and the in vitro cell activity degree without the drug carrier inhibitor is higher.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. A mechanistic analysis system for drug targets in depression and drug addiction diseases comprising selection of suitable subjects (1), subjects (6), drug treatment (14), protein detection (13) and immune tissue screening (18), characterized in that: the method comprises the following steps:
the method comprises the following steps: selecting a mouse group with more active vital signs from a young healthy mouse group as an experimental group;
step two: carrying out pathological treatment on the selected mouse group, putting addictive drugs into the mouse group feed to enable the mouse group to generate dependence on the drugs, feeding the mouse group in a closed and narrow dark environment, and culturing for several days, and then taking the mouse group as an experimental object;
step three: classifying experimental mouse group objects, injecting different carrier protein inhibitors into the experimental mouse group objects in different types of experimental mouse groups, injecting therapeutic drugs into the experimental mouse groups after the inhibitors are injected, and screening effective carrier protein inhibitors by observing the activity conditions of the experimental mouse groups;
step four: adding marked fluorescein into the drug molecules of another group of experimental mice, observing the drug molecules through a microscope, selecting the successfully marked drug molecules, injecting the marked drug molecules into the experimental mice, acting for a period of time, and taking out the brain cells of the mice;
step five: after the brain cells are taken out, different tissues in the brain cells are separated by adopting a low-speed centrifugation technical means, the different tissues are observed through a microscope, the specific action area of the drug molecules is obtained, and the experimental result is analyzed and recorded.
2. The system of claim 1, wherein the system comprises: the output end of the selected suitable object (1) is respectively connected with the input ends of the depressive processing (2) and the drug addiction processing (3), the output ends of the depressive processing (2) and the drug addiction processing (3) are respectively connected with the input end of the screening object (4), and the output end of the screening object (4) is connected with the input end of the acquisition experimental object (5).
3. The system of claim 1, wherein the system comprises: the output of subject (6) and the input interconnect of injection treatment medicine (7), the output of injection treatment medicine (7) and the input interconnect of adding different carrier protein inhibitor (8), the output of adding different carrier protein inhibitor (8) and the input interconnect of observing subject sign condition (9), the output of observing subject sign condition (9) and the input interconnect of screening carrier protein inhibitor (10).
4. The system of claim 1, wherein the system comprises: the output of subject (6) and the input interconnect of injection treatment medicine (7), the output of injection treatment medicine (7) and the input interconnect of drawing materials (11) in brain district, the output of drawing materials (11) in brain district and the input interconnect of acquireing brain district protein (12), the output of acquireing brain district protein (12) and the input interconnect of protein detection (13).
5. The system of claim 1, wherein the system comprises: the output end of the drug treatment (14) is connected with the input end of the drug molecular marker (15), the output end of the drug molecular marker (15) is connected with the input end of the marker drug screening (16), and the output end of the marker drug screening (16) is connected with the input end of the marker drug storage (17).
6. The system of claim 1, wherein the system comprises: the input end of the protein detection (13) is connected with the input end of an immune tissue screening (18), the output end of the immune tissue screening (18) is connected with the input end of a marking area observation (19), and the output end of the marking area observation (19) is connected with the input end of a medicine action position acquisition (20).
7. The system of claim 1, wherein the system comprises: the output end of the experimental object (6) is respectively connected with the input ends of the protein carrier inhibitor (21) and the physiological saline (22), and the output ends of the protein carrier inhibitor (21) and the physiological saline (22) are respectively connected with the input end of the screening object (4).
8. The system of claim 1, wherein the system comprises: the output end of the immune tissue screening (18) is connected with the input end of the low-speed centrifugal screening (23), the output end of the low-speed centrifugal screening (23) is connected with the input end of the different cell tissues (24), and the output end of the different cell tissues (24) is connected with the input end of the classified storage (25).
9. The system of claim 1, wherein the system comprises: the output end of the experimental object (6) is connected with the input end for obtaining the brain tissue cells (26), and the output end for obtaining the brain tissue cells (26) is connected with the input end for in vitro cell culture (27).
10. The system of claim 9, wherein the system comprises: the output end of the cell in-vitro culture (27) is respectively connected with the input ends of a protein carrier inhibitor (21) and physiological saline (22), the output ends of the protein carrier inhibitor (21) and the physiological saline (22) are respectively connected with the input end of an injection therapeutic drug (7), and the output end of the injection therapeutic drug (7) is connected with the input end of an observation cell shape (28).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110589629.4A CN113337570A (en) | 2021-05-28 | 2021-05-28 | Mechanism analysis system for drug target of depression and drug addiction disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110589629.4A CN113337570A (en) | 2021-05-28 | 2021-05-28 | Mechanism analysis system for drug target of depression and drug addiction disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113337570A true CN113337570A (en) | 2021-09-03 |
Family
ID=77472587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110589629.4A Pending CN113337570A (en) | 2021-05-28 | 2021-05-28 | Mechanism analysis system for drug target of depression and drug addiction disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113337570A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113322299A (en) * | 2021-05-28 | 2021-08-31 | 南昌大学 | Drug target recognition method for depression and drug addiction diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016137841A1 (en) * | 2015-02-26 | 2016-09-01 | William Paterson University Of New Jersey | Transgenic mice |
| CN113322299A (en) * | 2021-05-28 | 2021-08-31 | 南昌大学 | Drug target recognition method for depression and drug addiction diseases |
-
2021
- 2021-05-28 CN CN202110589629.4A patent/CN113337570A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016137841A1 (en) * | 2015-02-26 | 2016-09-01 | William Paterson University Of New Jersey | Transgenic mice |
| CN113322299A (en) * | 2021-05-28 | 2021-08-31 | 南昌大学 | Drug target recognition method for depression and drug addiction diseases |
Non-Patent Citations (2)
| Title |
|---|
| 梁建辉: "酒精成瘾治疗药物药理活性筛选和药效学评价技术平台的研究", 《山西大同大学学报(自然科学版)》 * |
| 邱天云: "海马和伏隔核脑区细胞膜GABABR对抑郁症发生发展的作用与机制研究", 《中国优秀硕士学位论文全文数据库（医药卫生科技辑）》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113322299A (en) * | 2021-05-28 | 2021-08-31 | 南昌大学 | Drug target recognition method for depression and drug addiction diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| May-Zhang et al. | Combinatorial transcriptional profiling of mouse and human enteric neurons identifies shared and disparate subtypes in situ | |
| da Costa et al. | How thalamus connects to spiny stellate cells in the cat's visual cortex | |
| Cousin et al. | RINT1 Bi-allelic variations cause infantile-onset recurrent acute liver failure and skeletal abnormalities | |
| Shekhar et al. | Generating and using transcriptomically based retinal cell atlases | |
| CN101810866A (en) | New method for screening anti-liver injury medicament by using model organism zebra fish | |
| CN108664769A (en) | Large-scale medicine method for relocating based on cancer gene group and non-specific gene label | |
| CN113142135A (en) | Construction method of digestive tract tumor PDX model and standardized model library | |
| CN113337570A (en) | Mechanism analysis system for drug target of depression and drug addiction disease | |
| Hu et al. | Hippocampal subfield alterations in schizophrenia: a selective review of structural MRI studies | |
| Cui et al. | Characteristics of neural growth and cryopreservation of the dorsal root ganglion using three-dimensional collagen hydrogel culture versus conventional culture | |
| Giffin et al. | Differential expression of voltage-gated calcium channels in identified visual cortical neurons | |
| Schubert | On the origin of cell functions encoded in the toponome | |
| Sharlaimova et al. | Coelomocyte replenishment in adult Asterias rubens: the possible ways | |
| Ye et al. | Unraveling the complex pathophysiology of white matter hemorrhage in intracerebral stroke: A single‐cell RNA sequencing approach | |
| Stewart et al. | Bioelectricity and epimorphic regeneration | |
| CN106929577A (en) | A kind of lncRNA biomarker related to adenocarcinoma of lung | |
| Gordon et al. | Evaluating whole-genome expression differences in idiopathic and diabetic adhesive capsulitis | |
| CN108624680B (en) | The application of RAE1 gene or albumen as the biomarker of diagnosing myocardial infarction | |
| AU2022417277B2 (en) | Method for screening refreshing drug and application of asperuloside in refreshing | |
| Mitchell et al. | Generating widespread and scalable retinal lesions in adult zebrafish by intraocular injection of ouabain | |
| CN113322299A (en) | Drug target recognition method for depression and drug addiction diseases | |
| CN108660204A (en) | Applications of the lncRNA on the product for preparing diagnosis or treatment osteoarthritis | |
| CN105251006B (en) | Purposes of the TLR3 inhibitor in the drug for preparing treatment cocaine habituation | |
| Montgomery et al. | Tissue-resident, extravascular Ly6c− monocytes are critical for inflammation in the synovium | |
| CN102154434B (en) | Method for detecting materials causing anaphylactoid reaction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |